CTOs on the Move

Code Biotherapeutics

www.codebiotx.com

 
Code Bio was founded on the belief that more can be done for people living with debilitating genetic diseases. We are driven by the potential of our transformative technology to treat the untreatable and cure the incurable. Code Bio is developing highly targeted genetic medicines with its proprietary, novel, multivalent, synthetic DNA delivery platform, 3DNA®, which has been engineered to overcome many of the challenges inherent with the delivery of genetic medicines. 3DNA offers unparalleled tissue and cell targeting specificity, improved bioavailability, capability to deliver large genetic payloads, potential ability to re-dose, and a scalable, modular, reproducible manufacturing process. Our ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Alexander Tracy
Chief Technical Officer Profile

Funding

Code Biotherapeutics raised $10M on 04/20/2021
Code Biotherapeutics raised $75M on 06/07/2022

Similar Companies

Adolor Corporation

Adolor Corporation is a Exton, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Panomics

Panomics is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Meridian Health Services

Meridian Health Services is a progressive healthcare organization specializing in “whole person” health, integrating physical, mental and social well-being. The focus on a broader spectrum of health including primary medical care, behavioral health and human services offers a well-rounded approach for happier, healthier patients. Meridian Health Services has been serving the community for over 35 years and is accredited by the Joint Commission and certified by the Indiana Division of Mental Health and Addictions.

Cannabis Science

Cannabis Science is a Colorado Springs, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Decibel Therapeutics

Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel`s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of a world in which the privileges of hearing and balance are available to all.